FANCD2 is one of a number of proteins in the FANC group. It undergoes modification in both its normal and disease state; therefore our FANCD2 antibodies are modified and conjugated in various ways for research.
FANCD2 (Fanconi Anaemia Complementation Group D2) is one of several FANC proteins involved with development of Fanconi Anaemia, a genetic disease that increases cell susceptibility to tumour development. In its normal pathway it interacts with several other genes known to cause cancer, for example BRCA1.
FANCD2 is routinely modified by interaction with other proteins, to enable it to carry out normal tasks. The protein occurs in all cells and plays a role in DNA-repair, inhibiting DNA synthesis following exposure to ionizing radiation, as well as resisting cross-linking. It also activates S-phase checkpoints following phosphorylation by ATM. It has been shown FANCD2 may also be part of the DNA repair mechanism, repairing double-strand breaks.
Immunocytochemistry/Immunofluorescence: FANCD2 Antibody
However, if FANCD2 undergoes mutation, this can result in decreased apoptosis (programmed cell death), tumours development and so on. Similarly, BRCA1 (early onset breast cancer gene 1) is normally a tumour suppressor protein. However, the mutated form can fuse with FANCD2 during exposure of the cell to radiation, to create nuclear foci. Mutated FANCD2 can fuse with normal BRCA1under the same conditions.
The use of FANCD2 and BRCA1 antibodies has therefore concentrated on both normal cell function, and the role of these proteins in tumour development. We at Novus Biologicals have modified FANCD2 antibody in fused and phosphorylated form. This allows researchers to look at specific areas of its mechanism of action.
Novus Biologicals offers many FANCD2 reagents for your research needs including:
